Analysis of Biomarkers From Patients With Chorioretinal Diseases

NCT02026843 | Recruiting DMC

• 1 other identifier: KNUH2013-1
• Study Type: observational
• Target: 100
• Locations: 1 country
• Sites: 1

Brief Summary

This study was conducted to investigate the levels of ocular biomarkers from the patients with chorioretinal diseases including diabetic retinopathy, retinal vascular diseases, age-related macular degeneration (dry and wet), and retinal degeneration.

Conditions

Diabetic Retinopathy; Macular Degeneration

Outcome Measures

Primary Outcomes (1)

• Biomarkers in ocular fluids

  To establish if certain type of chorioretinal diseases group are associated to different concentrations of gene or protein concentration.

  one month

Study Arms (2)

Chorioretinal diseases

chorioretinal diseases including diabetic retinopathy, retinal vascular diseases, age-related macular degeneration (dry and wet), and retinal degeneration.

Drug: Chorioretinal diseases

Control

control patients with surgeries include pars plana vitrectomy of macular hole, epiretinal membrane, cataract surgery.

Interventions

Chorioretinal diseases DRUG

chorioretinal diseases including diabetic retinopathy, retinal vascular diseases, age-related macular degeneration (dry and wet), and retinal degeneration

Chorioretinal diseases

Eligibility Criteria

• Age: 20 Years - 80 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

A total of 100 patients will be included. 50 patients with chorioretinal diseases including diabetic retinopathy, retinal vascular diseases, age-related macular degeneration (dry and wet), and retinal degeneration. and 50 control patients scheduled for pars plana vitrectomy for nondiabetic retinal disease or phacoemulsification.

You may qualify if:

• age over 20 years
• patients requiring ophthalmologic treatments for different degrees of decreasing of visual acuity.
• patients with chorioretinal diseases including diabetic retinopathy, retinal vascular diseases, age-related macular degeneration (dry and wet), and retinal degeneration.
• control patients asking cataract surgery or vitrectomy for posterior segment nonproliferative disorders.

You may not qualify if:

• under the age of 20 years
• patients that received any anti-vascular endothelial growth factor agent for proliferative disease before taking sample of aqueous humor
• patients that did not signed the informed consent of the trial
• patients with intraocular inflammations or infections that requiring any pharmaceutical agent
• patients with recent ocular trauma

Sponsors & Collaborators

• Kyungpook National University Hospital: lead

Study Sites (1)

Dong Ho Park

Daegu, Kyungsangpookdo, 700-721, South Korea

RECRUITING

Biospecimen

Retention: SAMPLES WITH DNA

certain gene or protein levels in ocular fluid

MeSH Terms

Conditions

Diabetic Retinopathy; Macular Degeneration

Condition Hierarchy (Ancestors)

Retinal Diseases; Eye Diseases; Diabetic Angiopathies; Vascular Diseases; Cardiovascular Diseases; Diabetes Complications; Diabetes Mellitus; Endocrine System Diseases; Retinal Degeneration

Study Officials

• Dong Ho Park, M.D

  Kyungpook National University Hospital

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Dong Ho Park, M.D.

CONTACT

82-53-420-5813; sarasate2222@gmail.com

Study Design

• Study Type: observational
• Observational Model: CASE CONTROL
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Department of Opthalmology, School of medicine, Kyungpook National University

Study Record Dates

• First Submitted: December 29, 2013
• First Posted: January 3, 2014
• Study Start: April 1, 2012
• Primary Completion (Estimated): February 1, 2028
• Study Completion (Estimated): April 1, 2031
• Last Updated: March 6, 2025

Record last verified: 2025-03

Data Sharing

• IPD Sharing: Will not share

Locations

KR (1)